An intranasal formulation of AstraZeneca's widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong ...

The U.S. FDA has given the green light for AstraZeneca's FluMist nasal spray vaccine to be self-administered or administered ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

Nasal vaccines could still be a powerful weapon in the fight against Covid-19 despite “disappointing” recent trial results for an AstraZeneca spray, experts say. By entering the body the same ...

Here intranasal vaccines may achieve what OPV ... adenoviruses naturally infect mucosal tissue. For e.g. the AstraZeneca IN vaccine trials that are currently ongoing, the challenge would seem ...

In AstraZeneca’s trial, 100% of adults were able to administer a full dose to themselves. The ease of giving the nasal spray ...

(Reuters) -The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for self-administration, making it the first of its kind. FluMist is the first ...

HUNTINGTON, W.Va. (WSAZ) - A new flu vaccine is on its way, and this one can be administered at home. The FDA has approved AstraZeneca’s FluMist Nasal Spray to be used outside a healthcare setting.

who formed the University of Oxford team that developed the vaccine marketed by AstraZeneca, pointed out to the UK’s Commons Science and Technology Committee that there is already a nasal ...

On April 30, AstraZeneca admitted that the vaccine, sold under the name Vaxzevria, can cause fatal blood clots and low platelet counts, also known as thrombosis syndrome with thrombocytopenia ...

AstraZeneca made headlines on Tuesday as it initiated the global withdrawal of its COVID-19 vaccine. This decision comes weeks after the pharmaceutical giant acknowledged the vaccine's potential ...

“At the current time, the use of the Pfizer vaccine is preferred over the AstraZeneca vaccine in adults aged less than 50 years who have not already received a first dose of AstraZeneca vaccin ...